Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Price Down 0.6% – What’s Next?

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)’s stock price traded down 0.6% on Thursday . The company traded as low as $90.82 and last traded at $91.12. Approximately 21,979 shares changed hands during mid-day trading, an increase of 80% from the average session volume of 12,240 shares. The stock had previously closed at $91.69.

Invesco Biotechnology & Genome ETF Trading Down 0.6%

The company’s 50 day moving average is $88.17 and its 200-day moving average is $83.30. The company has a market capitalization of $287.03 million, a P/E ratio of 20.44 and a beta of 0.70.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Colonial Trust Advisors purchased a new position in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at approximately $25,000. Fifth Third Bancorp bought a new position in Invesco Biotechnology & Genome ETF during the 1st quarter valued at approximately $30,000. Comerica Bank raised its stake in Invesco Biotechnology & Genome ETF by 86.2% during the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after buying an additional 175 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after buying an additional 245 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the third quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after acquiring an additional 342 shares in the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.